Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial

Immunotherapy

The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial

Allergy

Gappa M, Gagnon R, Horak F, Cichocka-Jarosz E, Dalgaard T, Hargreaves K, Mikler J, Emeryk A, Hansen KS, Pfaar O

doi: 10.1111/all.16363

Melanoma and Skin Cancer

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Lancet Oncol

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM

doi: 10.1016/S1470-2045(24)00338-3

Further Publications Dermatology

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials

J Eur Acad Dermatol Venereol

Calabrese L, Cartocci A, Rubegni P, French LE, Kendziora B

doi: 10.1111/jdv.20617

Immunodeficiency

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

Clin Immunol

Rao VK, Šedivá A, Dalm VASH, Plebani A, Schuetz C, Shcherbina A, Trizzino A, Zharankova Y, Orpia A, Kulm E, Webster S, Körholz J, Lougaris V, Rodina Y, Conlon N, Coulter T, Bradt J, Relan A, Uzel G

doi: 10.1016/j.clim.2024.110400

Rosacea

Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials

JAMA Dermatol

Bhatia N, Del Rosso J, Stein Gold L, Lain E, Draelos ZD, Sidgiddi S, MVOR-1 and MVOR-2 Study Investigators

doi: 10.1001/jamadermatol.2024.6542

Further Publications Immunology

A Streamlined Strategy for Basophil Activation Testing in a Multicenter Phase III Clinical Trial

J Allergy Clin Immunol Pract

Suárez-Fariñas M, Grishin A, Arif-Lusson R, Bourgoin P, Matthews K, Campbell DE, Busnel JM, Sampson HA

doi: 10.1016/j.jaip.2024.09.007

Further Publications Dermatology

Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study

Adv Ther

Bernstein JA, Betschel SD, Busse PJ, Banerji A, Wedner HJ, Manning M, Zaragoza-Urdaz RH, Anderson J, Gagnon R, Baptist AP, Soteres D, Lumry WR, Craig T, Petroni D, Hsu FI, Nova Estepan D, Juethner S, Watt M, Khutoryansky N, Zuraw BL, EMPOWER Investigators

doi: 10.1007/s12325-025-03226-3

Osteoarthritis

Impact of Structural Severity on Outcomes in Knee Osteoarthritis: An Analysis of Data from Phase 2 and Phase 3 Lorecivivint Clinical Trials

Rheumatology (Oxford)

Tambiah J, Kennedy S, Swearingen C, McAlindon T, Yazici Y

doi: 10.1093/rheumatology/keae610

Rheumatoid Arthritis

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Ann Rheum Dis

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A

doi: 10.1136/ard-2024-226286

Related content